A Review of the Literature of Mirtazapine in Co-Occurring Depression and an Alcohol Use Disorder.

Autor:	Cornelius JR; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA., Chung TA; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA., Douaihy AB; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA., Kirisci L; University of Pittsburgh Medical Center, Pittsburgh, USA., Glance J; University of Pittsburgh Medical Center, Pittsburgh, USA., Kmiec J; University of Pittsburgh Medical Center, Pittsburgh, USA., Wesesky MA; University of Pittsburgh Medical Center, Pittsburgh, USA., FitzGerald D; University of Miami, Miami, USA., Salloum I; University of Miami, Miami, USA.
Jazyk:	angličtina
Zdroj:	Journal of addictive behaviors, therapy & rehabilitation [J Addict Behav Ther Rehabil] 2016; Vol. 5 (4). Date of Electronic Publication: 2016 Dec 30.
DOI:	10.4172/2324-9005.1000159
Abstrakt:	Background: Prior medication studies involving individuals with major depression in combination with an alcohol use disorder (MDD/AUD) have mainly focused on SSRI and tricyclic antidepressants, with generally ineffective results. Consequently, effective treatments for that common comorbid condition remain elusive. Mirtazapine is an antidepressant medicine with a unique pharmacological profile, whose effectiveness for treating non-comorbid depression reportedly may exceed that of SSRIs. Objective/methods: We now review the published literature regarding the tolerability and efficacy of mirtazapine for the treatment of the depression and the pathological alcohol ingestion of individuals with co-occurring MDD/AUD, including a review of four of our own small studies and two studies conducted outside the United States. Results/conclusions: The findings of these studies suggest that mirtazapine is well tolerated among persons with comorbid MDD/AUD. Results also provide some evidence of efficacy for mirtazapine for decreasing the level of depression of persons with co-occurring MDD/AUD, and suggest that decreases in depression may occur relatively quickly after starting treatment, but provide no evidence of effectiveness for decreasing the level of alcohol ingestion. Large-scale double-blind, placebo-controlled studies are warranted to further clarify the tolerability and efficacy of mirtazapine among individuals with MDD/AUD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu